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Background: To investigate relationship between glycated hemoglobin (HbA1c) level and coronary artery disease
(CAD) severity.
Methods: Observational study was conducted and 573 participants were enrolled and baseline characteristics were
collected. Clinical presentations in terms of stable angina, unstable angina or acute myocardial infarction were
diagnosed. All participants were performed coronary angiography to figure out the numbers of coronary artery
stenosis in terms of none-stenosis (< 50% stenosis), single or multiple vessels stenoses (≥ 50% stenosis). All
participants were divided into subgroups according to two categories in terms of severity of clinical presentation
(stable angina, unstable angina, or acute myocardial infarction) and the number of coronary artery stenosis (none,
single, and multiple vessels). Primary endpoint was to evaluate relationship between baseline HbA1c value and
CAD severity.
Results: Consistent to previous studies, participants with CAD had more risk factors such as elderly, smoking, low
HDL-C and high CRP levels. Notably, HbA1c level was more prominent in CAD group than that without CAD. As
compared to stable angina subgroup, HbA1c levels were gradually increased in unstable angina and acute
myocardial infarction groups. Similar trend was identified in another category in terms of higher HbA1c level
corresponding to more vessels stenoses. Multivariate regression analyses showed that after adjusted for traditional
risk factors as well as fasting blood glucose, HbA1c remained strongly associated with the severity of CAD.
Nonetheless, there was no significant association when CRP was accounted for.
Conclusion: HbA1c may be a useful indicator for CAD risk evaluation in non-diabetic adults.
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Diabetes mellitus is a major and well established risk fac-
tor for macro-vascular diseases such as atherosclerotic
cardiovascular diseases (ASCVD) and micro-vascular
diseases such as neural, renal and retinal diseases [1,2]. Of
note, in patients with diabetes, plasma glucose level is
significantly associated with the incidence and severity of
micro-vascular and macro-vascular complications [1].
Currently, owing to its advantages over fasting blood glu-
cose such as low intra-individual variability and being* Correspondence: gdghllw@163.com
†Equal contributors
Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong
General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan
Road 2, Guangzhou 510080, China
© 2014 Cai et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.capable of evaluating the long-term blood glucose control
[3,4], glycated hemoglobin (HbA1c), a parameter of aver-
age blood glucose levels over 12 weeks, has also been sug-
gested using in clinical practice currently [5,6]. Evidence
from epidemiological studies also showed that as com-
pared to fasting blood glucose, HbA1c was more strongly
associated with the risks of ASCVD and mortality from
any causes [7,8], which further supported the notion that
HbA1c was superior to fasting blood glucose in predicting
ASCVD outcomes. Nevertheless, some drawbacks regard-
ing HbA1c, including un-satisfactory correlation with fast-
ing blood glucose and over-diagnosis among patients with
anemia and renal dysfunction, have also aroused concerns
with respect to its application for diabetic diagnosis and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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between HbA1c and cardiovascular outcomes in popula-
tions without diabetes are still uncertain. For example,
Silbernagel et al. reported that HbA1c significantly and in-
dependently of fasting blood glucose predicted all-cause of
cardiovascular death in white population without diabetes
[7]. Garg N and colleagues showed that in non-diabetics,
HbA1c level has a linear incremental association with
ASCVD [11]. Nonetheless, data from the Emerging Risk
Factors Collaboration revealed that HbA1c merely added
little incremental benefit for ASCVD risk prediction in
patients without known ASCVD and diabetes [12].
In light of previous findings, our current study was de-
signed to evaluate whether HbA1c level was associated
with the severity of coronary artery diseases (CAD) in
populations without diagnostic diabetes, and we believed
that the clinical implication of our study would add, if
any, valuable information to address whether HbA1c
level could be used to predict the ASCVD risk in
non-diabetic population.
Methods
Studied populations and protocols
Studied populations were enrolled from June of 2013 to
April of 2014 after informed consent was obtained, and
this study was approved by the Ethical Committee of
Guangdong General Hospital. Current research is a retro-
spective and observational research, therefore, the includ-
ing criteria are subjects with definitive coronary artery
condition in terms of none-significant, single or multiple
vessels stenoses as assessed by angiographic examination,
and the excluding criteria are subjects without angio-
graphic examination, with significant hepatic or renal
dysfunction, anemia, tumor or connective tissue dis-
eases. Clinical presentations in terms of stable angina,
unstable angina or acute myocardial infarction were
diagnosed according to their clinical manifestation, elec-
trocardiography characteristics and cardiac biomarkers
by two experts of cardiology. All participants were
performed coronary angiography to definitely figure out
the numbers of coronary artery stenosis in terms of
none-significant (< 50% stenosis), single or multiple ves-
sels stenoses (≥ 50% stenosis). Baseline characteristics
including age, gender, family history of ASCVD, smok-
ing status, hypertension, serum levels of lipid profile,
fasting blood glucose, C-reactive protein (CRP) and
HbA1c were collected at admission. In order to better
understand whether HbA1c level was associated with
the severity of CAD, all participants were divided into
different subgroups according to two major categories
in terms of the severity of clinical presentation (stable
angina, unstable angina, or acute myocardial infarction)
and the number of coronary artery stenosis (none,
single, and multiple vessels stenoses).Studied endpoint
The primary endpoint of current study was to evaluate
the relationship between HbA1c level and the severity of
CAD. In addition, whether HbA1c was an independent
risk indicator for the severity of CAD was also evaluated.
Statistical analyses
Continuous data was presented as mean ± SD or median
(interquartile range) appropriately, and compared by the
Student’s t-test when data was normally distributed, other-
wise compared by the Wilcoxon rank-sum test. Categorical
data was presented as percentage and compared by χ2 test.
Univariate and multivariate regression analyses were
performed to evaluate the relationship between HbA1c
value and the severity of coronary artery diseases. Statistical
analyses were performed by using SPSS software version




Totally 573 participants were enrolled and initially divided
into two groups, namely without CAD group and CAD
group, according to their coronary angiography examin-
ation. Since our current study was an observational study
and therefore it was understandable and rational that the
risk factors or comorbidities were more prevalent in the
CAD group than that of without CAD group (as presented
in Table 1). In the CAD group, age was older, male pre-
dominance, higher percentage of smoking and lower high
density lipoprotein-cholesterol (HDL-C) level. No signifi-
cant difference of total cholesterol (TC), triglyceride (TG),
low density lipoprotein-cholesterol (LDL-C), renal func-
tion and fasting blood glucose were found between these
two groups, except serum levels of CRP and HbA1c were
significantly higher in the CAD group than that of without
CAD group. Baseline characteristics among clinical
subgroups were compared additionally. As presented in
Table 2, risk factors including aging and smoking were
more prevalent in the acute myocardial infarction group
as compared to the stable angina group (p < 0.05). Serum
level of CRP was significantly higher while apoA level was
profoundly lower in the acute myocardial infarction when
compared to the table angina group (p < 0.05).
Comparison of HbA1c levels among subgroups of CAD
In order to evaluate the relationship of HbA1c level and
severity of CAD, all CAD patients (n = 466) were divided
into different subgroups according to two major categories
as described above. In the first category, all CAD patients
were divided into stable angina, unstable angina and acute
myocardial infarction groups. As shown in Figure 1A, the
difference of HbA1c level among each subgroup was
significantly different, with a p-trend value < 0.05. In the
Table 1 Baseline characteristics
Variable Without CAD (n = 107) CAD (n = 466) P value
Age (years) 60.5 ± 12.1 63.83 ± 11.0 0.006
Male (%) 66 (61.7) 355 (76.2) 0.002
Family history (%) 5 (4.7) 32 (6.9) 0.405
Smoking (%) 27 (25.2) 173 (37.1) 0.020
Hypertension (%) 50 (46.7) 273 (58.6) 0.260
TG (mmol/L) 1.51 ± 1.05 1.78 ± 1.50 0.078
TC (mmol/L) 4.44 ± 1.01 4.30 ± 1.13 0.264
LDL-C (mmol/L) 2.67 ± 0.87 2.62 ± 0.99 0.609
HDL-C (mmol/L) 1.11 ± 0.30 0.97 ± 0.23 < 0.001
ApoA (mmol/L) 1.24 ± 0.39 1.10 ± 0.31 <0.001
ApoB (mmol/L) 0.81 ± 0.60 0.77 ± 0.23 0.273
CRP (mg/L) 3.67 ± 0.60 12.12 ± 1.21 0.001
Cr (umol/L) 96.5 ± 10.1 97.2 ± 8.8 0.228
BUN (mmol/L) 6.60 ± 1.33 6.82 ± 1.07 0.164
FBG (mmol/L) 5.58 ± 0.76 5.26 ± 0.69 0.178
HbA1c (%) 6.05 ± 1.17 6.55 ± 1.38 0.001
Denote: TG = triglyceride, TC = total cholesterol, LDL-C = low density
lipoprotein-cholesterol, HDL-C = high density lipoprotein-cholesterol,
Cr = creatinine, BUN = blood urine nitrogen.
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significant stenosis, single vessel stenosis and multiple
vessels stenoses groups. As presented in Figure 1B, the
HbA1c level was significantly associated with the number
of coronary artery stenosis, with a p-trend value < 0.001.
Multivariate regression analyses
For the purpose of investigating whether HbA1c was an in-
dependent risk factor for the severity of CAD, multivariateTable 2 Comparisons of baseline characteristics of clinical sub
Variable None (n = 129) Sing
Age (years) 59.7 ± 10.4 61.6
Male (%) 90 (69.8) 64 (7
Family history (%) 8 (6.2) 6 (6.
Smoking (%) 41 (31.8) 33 (3
Hypertension (%) 72 (55.8) 52 (5
TG (mmol/L) 1.62 ± 0.21 1.71
TC (mmol/L) 4.65 ± 1.02 4.59
LDL-C (mmol/L) 2.82 ± 0.62 2.84
HDL-C (mmol/L) 1.08 ± 0.26 0.99
APOA (mmol/L) 1.29 ± 0.41 1.22
APOB (mmol/L) 0.82 ± 0.56 0.80
CRP (mg/L) 9.24 ± 1.08 10.86
Cr (umol/L) 96.8 ± 8.1 97.0
BUN (mmol/L) 6.67 ± 1.03 6.80
FBG (mmol/L) 5.22 ± 0.44 5.26regression analyses were performed. In the first category,
after adjustment for age, gender, family history of CAD,
smoking and hypertension (in model 1a), HbA1c was
strongly associated with the severity of CAD (P for trend =
0.010). Additional adjustment for TC, HDL-C, ApoA, and
fasting blood glucose, the association was attenuated but
HbA1c remained significantly associated with the severity
of CAD (P for trend = 0.043, in model 1b). Notably, with
adjustment for CRP (P for trend = 0.265, in model 1c),
there was no significant association between HbA1c and
the severity of CAD. In the second category, after adjust-
ment for age, gender, family history of CAD, smoking and
hypertension (in model 2a), there was a strongly relation-
ship between HbA1c and the number of coronary artery
stenosis (P for trend < 0.001). Additional adjustment for
TC, HDL-C, ApoA, and fasting blood glucose (in model
2b), HbA1c remained strongly associated with the number
of coronary artery stenosis (P for trend < 0.001). Similarly,
with adjustment for CRP (P for trend = 0.168, in model 2c),
there was no significant association between HbA1c and
the number of coronary artery stenosis.
Discussion
Currently, the predictive value of HbA1c on ASCVD risk
in non-diabetic population is still less certain, and the
application of HbA1c on ASCVD risk assessment among
different Cardiovascular Society is also still inconsistent.
Findings from our current study show that there is a sig-
nificant association between HbA1c level and the sever-
ity of CAD in non-diabetic population, even after
adjustment for traditional risk factors, and this relation-
ship is independent of fasting blood glucose. Nonethe-
less, we also observed that after adjustment for CRP,-groups
le (n = 87) Multi (n = 250) P value
± 11.3 64.2 ± 9.7 0.024
3.6) 355 (80.4) < 0.001
9) 32 (7.2) 0.113
7.9) 99 (39.6) 0.036
9.8) 149 (59.6) 0.218
± 0.18 1.73 ± 0.22 0.133
± 1.01 4.70 ± 1.05 0.428
± 0.55 2.86 ± 0.57 0.550
± 0.24 0.95 ± 0.20 0.446
± 0.36 1.13 ± 0.43 0.023
± 0.35 0.80 ± 0.47 0.204
± 1.12 13.65 ± 1.17 < 0.001
± 6.4 97.6 ± 8.2 0.523
± 1.01 6.82 ± 1.03 0.667
± 0.38 5.29 ± 0.62 0.216
Figure 1 Comparison of HbA1c levels among each subgroup in the two categories. Panel A, HbA1c levels comparison among stable,
unstable and AMI groups. Panel B, HbA1c levels comparison among none, single, and multiple vessels stenoses groups.
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the severity of CAD.
Knowingly, glycated hemoglobin is a stable parameter
reflecting approximately 3 months of blood glucose levels
and it has now been suggested using in clinical practice
for long-term blood glucose assessment in diabetic pa-
tients [1,13]. HbA1c is calculated as the ratio of glycated
to non-glycated N-terminal peptide of hemoglobin, and
the HbA1c level has been universally recognized as
important indicator for micro-vascular complications in
diabetic patients [13,14]. Nevertheless, whether HbA1c
level could also be used in macro-vascular diseases (such
as ASCVD) risk prediction is less clear, especially in non-
diabetic populations [15,16].
Accordingly, ASCVD is the leading cause of morbidity
and mortality worldwide and improvement of risk discrim-
ination is imperative [17]. Previously, results from previous
studies showed that for coronary heart diseases, risk dis-
crimination was significantly enhanced when HbA1c was
added in risk algorithm in non-diabetic patients [8,18,19].
Our current study also showed that as compared to stable
episode (stable angina), the levels of HbA1c were grad-
ually and significantly increased in unstable conditions
in terms of unstable angina and acute myocardial infarc-
tion, indicating that increased HbA1c level might resultin atherosclerotic plaque pro-rupture, and to our best
knowledge there were some mechanisms might partially
explain this finding. Biologically, glycated hemoglobin is
an advanced glycosylation end-product, and increased
HbA1c level could reflect more generation of advanced
glycosylation end-product, which might subsequently
abundantly attached to vessel wall causing endothelial
dysfunction and oxidative stress promotion [20,21]. On
the other hand, the binding of advanced glycosylation
end-product might also result in inflammatory cyto-
kines such as CRP over-production [22]. Increased CRP
level has been found significantly associated with the in-
stability of plaque [23,24], and this might partially explain
why after adjustment for CRP, there was no significant
association between HbA1c and the severity of CAD. Fi-
nally, increased advanced glycosylation end-product could
interfere with endogenous fibrinolytic system which might
result in higher risk of coronary artery stenosis [25,26].
Future experimental and clinical studies are warranted to
investigate whether reduced HbA1c level will improve
atherosclerosis plaque stability.
Other than the significant association between HbA1c
level and the severity of CAD, our current study also
showed that increased HbA1c level was associated
with more vessel stenoses in non-diabetic patients. As
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meability, promoting endothelium dysfunction, and en-
hancing inflammation and oxidative reaction, increased
advanced glycosylation end-product might lead to more
vessels stenoses.
Consistent with previous some epidemiological studies
[11,18,19,27], data from our study also revealed that after
adjusted for traditional risk factors including age, smoking,
TC, HDL-C, HbA1c remained strongly associated with the
severity of CAD. Notably, even after adjusted for fasting
blood glucose, an independent risk factor for ASCVD and
diabetes, there was still significant relationship between
HbA1c and the severity of CAD, further supporting
previous findings that HbA1c might be superior to fasting
blood glucose in the respects of CVD risk discrimination.
However, there was one distinctive discrepancy between
our research and previous studies [11,18,19,27] were that
we concomitantly evaluated the relationship between
HbA1c level and CAD severity including clinical scenario
severity and the number of coronary artery stenosis.
As compared to fasting blood glucose, HbA1c level
reflecting both fasting and post-prandial blood glucose
might also partially explain the superiority of HbA1c, be-
cause peak plasma glucose level might cause more severe
damage to endothelium [28,29]. Future study is warranted
to investigate whether there is significant interaction be-
tween post-prandial blood glucose and HbA1c on CVD
risk prediction. Notably, there was no significant associ-
ation between HbA1c and the severity of CAD when
adjusted for CRP. The underlying mechanism might be
ascribed to the increased CRP release when advanced
glycosylated end-product was elevated.
Conclusion
Our observational study found out that in non-diabetic
population, HbA1c level was significantly associated with
the severity of coronary artery diseases, which further
supporting the notion that HbA1c may be a useful and
independent indicator for CVD risk evaluation.
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